GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
Completed · Phase 2 · Has a placebo group
Conditions studied: Erythropoietic Protoporphyria (EPP)
In brief
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
Key facts
- Study ID
- NCT06971900
- Run by
- Portal Therapeutics, Inc.
- People needed
- 28
- Starts
- 2025-04-04
- Expected to finish
- 2025-11-24
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Celerion — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.